0
0
0
0
1
2
3
$0
Is AstraZeneca solid or fragile? The Finex Financial Health Scanner reads AZN's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $58.7B |
|---|---|
| Net income | $10.2B |
| Operating margin | 23.4% |
| Net margin | 17.4% |
| Cash and investments | $5.9B |
| Total debt | $30.3B |
| Free cash flow | $5.6B |
| Revenue growth (1 year) | 8.6% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.